Apyx Medical Reports Strong Q1 Revenue Growth, Significantly Narrows Losses, and Raises Full-Year Guidance
Summary
Apyx Medical reported robust Q1 2026 financial results, including a 32.4% revenue increase and a significant reduction in net and Adjusted EBITDA losses, leading to an upward revision of its full-year 2026 revenue guidance.
Key Events
-
Strong Q1 Revenue Growth
Total revenue for the first quarter of 2026 increased 32.4% to $12.5 million, up from $9.4 million in the prior year period, primarily driven by 36% growth in the Surgical Aesthetics segment.
-
Significantly Narrowed Losses
Net loss attributable to stockholders improved to $2.1 million, compared to a $4.2 million loss in Q1 2025. Adjusted EBITDA loss also significantly narrowed to $0.3 million from $2.4 million in the prior year.
-
Raised Full-Year 2026 Revenue Guidance
The company increased its full-year 2026 total revenue guidance to a range of $59.0 million to $60.0 million, up from the previous guidance of $57.5 million to $58.5 million.
-
Solid Cash Position
Apyx Medical reported cash and cash equivalents of $31.1 million as of March 31, 2026, with management projecting sufficient cash through 2027.
Analysis
Apyx Medical's first-quarter results demonstrate strong operational execution, with substantial revenue growth driven by its Surgical Aesthetics segment and the AYON Body Contouring System. The significant reduction in net loss and Adjusted EBITDA loss indicates improved financial health and efficiency. The decision to raise full-year revenue guidance signals management's increased confidence in continued growth and profitability, which is a strong positive indicator for investors. The company's cash position also provides a solid runway for operations through 2027.
At the time of this filing, APYX was trading at $3.34 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $122.1M. The 52-week trading range was $1.04 to $4.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.